nach oben

Erschienen in:

01.04.2016 | Original Article

Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer

verfasst von: S. Kaufmann, J. Bedke, S. Gatidis, J. Hennenlotter, U. Kramer, M. Notohamiprodjo, K. Nikolaou, A. Stenzl, S. Kruck

Erschienen in: World Journal of Urology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Multiparametric magnetic resonance imaging (mpMRI) improves diagnostic accuracy in re-biopsies of men with prostate cancer (PC) suspicion, but predictive value is limited despite the use of the new Prostate Imaging Reporting and Data System (PI-RADS). Prognostic value of the PC-specific biomarker prostate cancer gene 3 (PCA3) added to the PI-RADS score was evaluated.

Methods

The study was a retrospective analysis of the institutional database for men with MR-guided biopsy (MR-GB) for suspicious lesion in mpMRI and who had an additional pre-MR-GB PCA3 testing for ongoing PC suspicion. All men had ≥1 negative ultrasound GB. Lesions were retrospectively scored by PI-RADS in three MRI sequences (T2w, DCE, and DWI). PCA3 was analyzed with cutoffs of 25 and 35. The prognostic value of mpMRI and PCA3 and the additional value of both were explored.

Results

Tumor detection rate (49 men, mean PSA 10 ng/ml, lesion size 40 mm²) was 45 % (22/49 patients). In the subgroup of PI-RADS IV°, 17/17 patients had PC; in PI-RADS III° (intermediate) 5/15 had PC, and all 5 had a PCA3 >35. PCA3 >35 had no additional prognostic value in the whole cohort. Out of the 10/15 PC negative patients (PI-RADS III°), PCA3 was <35 in 6. The inclusion of PCA3 value in PI-RADS III° patients improved predictive accuracy to 91.8 %.

Conclusion

MpMRI and subsequent grading to PI-RADS significantly improves PC detection in the re-biopsy setting. The diagnostic uncertainty in the PI-RADS intermediate group can be ameliorated by the addition of PCA3 cutoff of 35 to avoid potential unnecessary biopsies.

Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30(2):213–218. doi:10.1007/s00345-011-0675-2 CrossRefPubMed

Jeong CW, Ku JH, Moon KC, Hong SK, Byun SS, Cho JY, Kim HH, Kim SH, Lee SE, Kwak C (2012) Can conventional magnetic resonance imaging, prostate needle biopsy, or their combination predict the laterality of clinically localized prostate cancer? Urology 79(6):1322–1327. doi:10.1016/j.urology.2012.01.080 CrossRefPubMed

van Hove A, Savoie PH, Maurin C, Brunelle S, Gravis G, Salem N, Walz J (2014) Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol 32(4):847–858. doi:10.1007/s00345-014-1332-3 CrossRefPubMed

Colleselli D, Schilling D, Lichy MP, Hennenlotter J, Vogel UH, Krueger SA, Kuehs U, Schlemmer HP, Stenzl A, Schwentner C (2010) Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection. Urol Int 84(4):388–394. doi:10.1159/000300572 CrossRefPubMed

Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, Corvin S, Sievert KD, Claussen CD, Stenzl A, Schlemmer HP (2006) MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 50(4):738–748. doi:10.1016/j.eururo.2006.03.007 (discussion 748–739) CrossRefPubMed

Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Futterer J, Bouwense S, van Oort I, Schroder F, Huisman H, Barentsz J (2012) Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 61(1):177–184. doi:10.1016/j.eururo.2011.08.042 CrossRefPubMed

Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ, European Society of Urogenital R (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757. doi:10.1007/s00330-011-2377-y CrossRefPubMedPubMedCentral

Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59(23):5975–5979PubMed

Busetto GM, De Berardinis E, Sciarra A, Panebianco V, Giovannone R, Rosato S, D’Errigo P, Di Silverio F, Gentile V, Salciccia S (2013) Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models. Urology 82(6):1355–1360. doi:10.1016/j.urology.2013.06.078 CrossRefPubMed

10.

Leyten GH, Wierenga EA, Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, Schalken JA, Mulders PF (2013) Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci 14(6):11347–11355. doi:10.3390/ijms140611347 CrossRefPubMedPubMedCentral

11.

Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Bollito E, Papotti M, Molineris I, Passera R, Regge D (2014) The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? J Urol 192(1):60–66. doi:10.1016/j.juro.2014.01.030 CrossRefPubMed

12.

Falco T, Shenouda G, Kaufmann C, Belanger I, Procaccini C, Charrois C, Evans M (2002) Ultrasound imaging for external-beam prostate treatment setup and dosimetric verification. Med Dosim 27(4):271–273. doi:10.1016/s0958-3947(02)00144-9 CrossRefPubMed

13.

Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494. doi:10.1016/j.eururo.2010.12.009 CrossRefPubMed

14.

D’Amico AV, Whittington R, Malkowicz S et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974. doi:10.1001/jama.280.11.969 CrossRefPubMed

15.

Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54(5):1081–1088. doi:10.1016/j.eururo.2008.06.071 CrossRefPubMed

16.

Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F (2007) Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 52(5):1309–1322. doi:10.1016/j.eururo.2007.08.006 CrossRefPubMed

17.

Zaytoun OM, Stephenson AJ, Fareed K, El-Shafei A, Gao T, Levy D, Jones JS (2012) When serial prostate biopsy is recommended: most cancers detected are clinically insignificant. BJU Int 110(7):987–992. doi:10.1111/j.1464-410X.2012.10958.x CrossRefPubMed

18.

Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, Locklin J, Baccala AA Jr, Rastinehad AR, Merino MJ, Shih JH, Wood BJ, Pinto PA, Choyke PL (2011) Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 258(2):488–495. doi:10.1148/radiol.10100667 CrossRefPubMedPubMedCentral

19.

De Luca S, Passera R, Bollito E, Milillo A, Scarpa RM, Papotti M, Coda R, Randone DF (2013) Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score. Anticancer Res 33(10):4657–4662PubMed

20.

Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69(3):532–535. doi:10.1016/j.urology.2006.12.014 CrossRefPubMed

21.

de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A (2011) Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 185(6):2119–2125. doi:10.1016/j.juro.2011.01.075 CrossRefPubMed

22.

Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF (2013) PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 190(1):64–69. doi:10.1016/j.juro.2013.02.018 CrossRefPubMed

23.

van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, Remzi M, Marberger M (2012) The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 109(3):360–366. doi:10.1111/j.1464-410X.2011.10377.x CrossRefPubMed

24.

Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schroder F, Lilja H (2010) Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 28(15):2493–2498. doi:10.1200/jco.2009.24.1968 CrossRefPubMedPubMedCentral

25.

Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, Witjes JA (2011) Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59(6):962–977. doi:10.1016/j.eururo.2011.02.034 CrossRefPubMed

26.

Kuru TH, Roethke MC, Rieker P, Roth W, Fenchel M, Hohenfellner M, Schlemmer HP, Hadaschik BA (2013) Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int 112(8):1080–1087. doi:10.1111/bju.12259 CrossRefPubMed

27.

Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62(6):986–996. doi:10.1016/j.eururo.2012.06.044 CrossRefPubMed

28.

Rosenkrantz AB, Lim RP, Haghighi M, Somberg MB, Babb JS, Taneja SS (2013) Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI. AJR Am J Roentgenol 201(4):W612–W618. doi:10.2214/ajr.12.10173 CrossRefPubMed

29.

Schimmoller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, Antoch G, Albers P, Blondin D (2013) Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol 23(11):3185–3190. doi:10.1007/s00330-013-2922-y CrossRefPubMed

30.

Schimmoller L, Quentin M, Arsov C, Hiester A, Kropil P, Rabenalt R, Albers P, Antoch G, Blondin D (2014) Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy. Eur J Radiol 83(12):2103–2108. doi:10.1016/j.ejrad.2014.08.006 CrossRefPubMed

Titel: Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer
verfasst von: S. Kaufmann
J. Bedke
S. Gatidis
J. Hennenlotter
U. Kramer
M. Notohamiprodjo
K. Nikolaou
A. Stenzl
S. Kruck
Publikationsdatum: 01.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 4/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1655-8

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Zonal NephRo Score: external validation for predicting complications after open partial nephrectomy

Stereoscopic (3D) versus monoscopic (2D) laparoscopy: comparative study of performance using advanced HD optical systems in a surgical simulator model

True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical efforts

Differences between intrinsic and extrinsic ureteropelvic junction obstruction related to crossing vessels: histology and functional analyses